Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock: A Multi-Center, Double Blind, Phase II Randomized Controlled Trial

NCT05969275 is registered in ClinicalTrials.gov with Ottawa Hospital Research Institute as lead sponsor.

NCT NCT05969275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05969275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock: A Multi-Center, Double Blind, Phase II Randomized Controlled Trial
Lead sponsor
Ottawa Hospital Research Institute
Phase
Phase 2
Overall status
Recruiting
Start date
February 14, 2024
Completion date
March 31, 2027
Enrollment
296 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

infections, inflammation, pathologic processes, sepsis, septic shock, shock, systemic inflammatory response syndrome